News

Dr Angelika Zarkali and Dr Mathieu Bourdenx have received the prestigious fellowship to lead vital research and develop their careers.

Researchers at UCL Queen Square Institute of Neurology have discovered that the amyloid precursor protein (APP) family is essential for healthy communication between brain cells.

We are pleased to announce the appointment of Professor Jonathan Schott as a new Group Leader, to support UK DRI at UCL in delivering its vision of healthy brain ageing for all.

'Everything is Connected' is an exhibition celebrating neurological research and collaborations between artists, researchers and communities.

A study led by Dr Marc Aurel Busche (UK DRI at UCL, UCL Queen Square Institute of Neurology) sheds light on the earliest stage of Alzheimer’s.

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer’s therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.

Enhancing levels of ‘healthy fats’ like omega-3s in the brain could be beneficial in motor neurone disease (MND) finds a new study in fruit flies and brain cells, led by UCL Queen Square Institute of Neurology researchers.

Subtle changes in the brain, detectable through advanced imaging, blood & spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington’s disease

Genetic differences that contribute to how long a person will live and their risk of Alzheimer’s disease have been identified by researchers at UCL Queen Square Institute of Neurology and the UK Dementia Research Institute (UK DRI).

New study led by Prof Karen Duff, Dr Naoto Watamura, & Dr Martha Foiani (UK DRI at UCL) with Prof Takaomi Saido (Riken Center for Brain Science, Japan) reveals insight into the early stages of toxic tau protein build-up in diseases like frontotemporal dementia (FTD)& Alzheimer's.

A loss of brain volume associated with new immunotherapies for Alzheimer’s disease may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue, finds a study led by UCL researchers.

UCL will work with the global construction firm Mace to complete our new world-leading neuroscience facility at 256 Grays Inn Road, London.

One of the UK’s largest philanthropic foundations has extended its support for the Neurogenetic Therapies Programme at UCL until 2029, enabling researchers to further advance treatments for neurodegenerative and dementia-causing diseases. 

The Medicines and Healthcare Products Regulatory Agency (MHRA) has licensed the immunotherapy drug, Lecanemab, for use in the early stages of Alzheimer’s disease in the UK, following decades of work supported by UCL research.

A study led by Dr Marc Aurel Busche (UK DRI at UCL) reveals a key role in Alzheimer’s progression for oligodendrocytes, as producers of harmful amyloid beta protein in the brain.